progression-free-survival

Documents about progression-free-survival

• Patients' Expectations About the Survival Benefits of Cancer Drugs Approved Based on Progression-Free Survival#1437996ClinicalTrials.gov
• Advanced Pancreatic Cancer#912791ClinicalTrials.gov
• An individualized nomogram for predicting progression-free survival in systemic anaplastic large cell lymphoma: a multicenter, retrospective, and internally validated study.#453146PubMed
• Apatinib Combined With Capecitabine Second-line Treatment of Advanced Gastric Cancer: a Single-arm Exploratory Clinical Pilot Trial#1369923ClinicalTrials.gov
• Determination of Immune Phenotype in Glioblastoma Patients#833548ClinicalTrials.gov
• Id and Rd Maintenance Regimens After Induction of Remission in Multiple Myeloma.#1429506ClinicalTrials.gov
• International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma#872547ClinicalTrials.gov
• Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (NSAI)#1319998ClinicalTrials.gov
• Mesenteric Lymph Node Metastasis and Nutritional Status After Bowel Resection for Ovarian Cancer#839444ClinicalTrials.gov
• Clinical Study on Triple Negative Breast Cancer With Chinese Medicine#1044302ClinicalTrials.gov
• The Predictive Value of CT-PET in Esophageal Cancer#1385603ClinicalTrials.gov
• Predicting progression-free survival in glioblastoma with neuroimaging and machine learning.#244370NCBI PubMed Central
• Adjuvant Treatment of Apatinib in Nasopharyngeal Carcinoma#837285ClinicalTrials.gov
• Cell-free DNA dynamics and progression-free survival in metastatic gastroesophageal adenocarcinoma: insights from the REGIRI-PRODIGE 58 ancillary study#370788HAL (France)
• PFS and OS of Patients With Advanced Neuroendocrine Cancer (NEN) After Systemic Treatment#979914ClinicalTrials.gov
• Baseline D-dimer as a predictor of immune checkpoint inhibitor efficacy in cancer#4693Europe PMC
• Sorafenib and FOLFIRI Regimen in 2nd Colorectal Cancer (CRC) After Failure of Oxaliplatin Treatment#1385369ClinicalTrials.gov
• The association of hypoxia-inducible factor-1 alpha expression, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio with three-year progression-free survival in locally advanced colorectal cancer patients#481477ARPHA OAI-PMH Endpoint
• Long-term radiological progression after resection of dysembryoplastic neuroepithelial tumors: patterns and prognostic factors#5512Europe PMC
• BENdamustine at Elevated Dose for Relapsed Follicular Lymphoma in Intensification Therapy and Transplantation (BENEFIT)#1282527ClinicalTrials.gov
• Treatment Response and Prognosis in Glioma Patients: Q Cell and Its Biological Characteristics#881009ClinicalTrials.gov
• Predicting progression-free survival in glioblastoma: influence of the perilesional oedema and white-matter disconnectome#422515Europe PMC
• Metformin for the Treatment of mCRC Patients Undergoing FOLFIRI Plus Target Therapy#429726ClinicalTrials.gov
• Study of Gemcitabine Maintenance Treatment in Patients With Extensive SCLC Patients#1044376ClinicalTrials.gov
• Explainable Machine Learning-Based Prediction of Progression-Free Survival in Prostate Cancer: Retrospective Cohort Study.#1415804NCBI PubMed Central
• Real-world Study for Patients With Advanced Hepatobiliary Tumors#1059592ClinicalTrials.gov
• Progression-free Survival After MWA Plus Durvalumab and Tremelimumab for Unresectable Locally Advanced Pancreatic Cancer#858236ClinicalTrials.gov
• Sintilimab, Chidamide, and Azacitidine for Untreated Stage I-II Extranodal NK/T-Cell Lymphoma#208453ClinicalTrials.gov
• Dasatinib in Combination With Melphalan and Prednisone to Treat Relapsed and Refractory Multiple Myeloma Patients#810571ClinicalTrials.gov
• Real-world EHR-derived progression-free survival across successive lines of therapy informs metastatic breast cancer risk stratification#133208bioRxiv / medRxiv
• Association Between Drug-related Cutaneous Adverse Events and Progression Free Survival in Patients Treated with Enfortumab Vedotin#905202ClinicalTrials.gov
• HF-SRT vs. HS-WBRT in Treating Patients With Brain Oligometastases#851369ClinicalTrials.gov
• Relationship between overall survival and progression-free survival with 18 F-FDG PET/CT metabolic parameters in metastatic breast cancer patients treated with CDK 4/6 inhibitors#310720AVESIS
• Predictive value of EGFR amplification and EGFRvIII mutation in EGFR-targeted therapy for recurrent glioblastoma: a systematic review#304159Europe PMC
• Salvage surgery following primary treatment in recurrent vestibular schwannoma: surgical outcomes and progression-free survival- a meta-analysis.#244227NCBI PubMed Central
• Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients With mCSPC#1377306ClinicalTrials.gov
• The Impact of Thromboprophylaxis on Progression Free Survival of Patients With Advanced Pancreatic Cancer#1454436ClinicalTrials.gov
• Follow-up the OS and PFS of Rituximab Biosimilar HLX01 and MabThera, in Untreated Subjects With CD20+ DLBCL#1088457ClinicalTrials.gov
• Epigenetic Biomarker for Osteosarcoma#1152135ClinicalTrials.gov
• Phase 2 Study With Abraxane (Nab®Paclitaxel) in Metastatic Colorectal Cancer#1418529ClinicalTrials.gov
• Study to Evaluate Progression Free Survival in Cancer Patients With Advanced Colorectal Carcinoma With AMT2003#861485ClinicalTrials.gov
• A functional prognostic model predicts progression-free survival in patients with relapsed chronic lymphocytic leukemia treated with ibrutinib + venetoclax.#1001057NCBI PubMed Central
• A Real-world Study of Indian Patients With Advanced Breast Cancer Treated With Ribociclib#1045414ClinicalTrials.gov
• A Randomized Study to Determine the Efficacy of a Taxane and Bevacizumab With or Without Capecitabine as First Line Chemotherapy in Patients With Metastatic Breast Cancer#1162134ClinicalTrials.gov
• Real-world EHR-derived progression-free survival across successive lines of therapy informs metastatic breast cancer risk stratification#135527Unpaywall
• Supplementary Material for: Progression-free survival effect sizes in randomized controlled trials of targeted cancer therapies with positive outcomes#333580Figshare
• Dara-PD in the Treatment of Patients With First Relapse of Multiple Myeloma#857959ClinicalTrials.gov
• Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer#898516ClinicalTrials.gov
• Automated Deauville Score computation from baseline [¹⁸F]FDG PET/CT predicts progression-free survival in multiple myeloma: a radiogenomic framework.#1189266NCBI PubMed Central
• Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma#978953ClinicalTrials.gov